Antibody-Drug Conjugate MIRV Improves OS in Ovarian Cancer Antibody-Drug Conjugate MIRV Improves OS in Ovarian Cancer

In the phase 3 MIRASOL study, the antibody-drug conjugate MIRV produced an overall survival benefit in women with platinum-resistant ovarian cancer.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news